Onsite registration is available as space allows.
Please see registration staff in San Francisco.


CME Breakfast Symposium
7:00 AM - 11:00 AM

Moscone West | 2nd Floor
800 Howard Street, San Francisco, CA
(at the corner of Fourth & Howard Streets)
Rooms 2008/2010

7:00 AM Registration/Breakfast
7:40 AM Welcome
  Lee Greenberger, PhD
Chief Scientific Officer, The Leukemia & Lymphoma Society
7:45 AM Introduction
  Owen A. O’Connor, MD, PhD
7:50 AM PD-1 and the Landscape Beyond: Unleashing Immune Responses Against Hematologic Cancer Using Antibodies Targeting Immune Checkpoints
  Alexander M. Lesokhin, MD
8:20 AM Small Molecule Immunomodulatory Drugs
  John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
8:50 AM Priming T Cells Against EBV
  Helen E. Heslop, MD, DSc (Hon)
9:20 AM CAR T Cells: The CD19 Paradigm
  Michel Sadelain, MD, PhD
9:50 AM Antibody Drug Conjugates: Selectively Delivering Potent Cytotoxic Agents to Ablate Cancer Cells*
  Eric Sievers, MD
10:20 AM Panel Discussion and Q&A:
How Do We Operationalize and Move Immunologic Strategies Forward in a Timely Fashion?
  Owen A. O’Connor, MD, PhD
Alexander M. Lesokhin, MD
John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Helen E. Heslop, MD, DSc (Hon)
Michel Sadelain, MD, PhD

*Dr. Sievers' presentation is not for CME credit


Owen A. O’Connor, MD, PhD
Professor of Medicine and Experimental Therapeutics
Director, Center for Lymphoid Malignancies
Columbia University Medical Center
New York Presbyterian Hospital
New York, NY

Alexander M. Lesokhin, MD
Assistant Attending Physician, Myeloma Service and Immunotherapeutics Core
Memorial Sloan Kettering Cancer Center
New York, NY

John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Chair of Medical Oncology
Barts Cancer Institute
Barts and the London School of Medicine and Dentistry, Queen Mary University of London
London, UK

Helen E. Heslop, MD, DSc (Hon)
Dan L. Duncan Chair
Interim Director, Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX

Michel Sadelain, MD, PhD
Stephen and Barbara Friedman Chair
Director, Center for Cell Engineering
Member, Immunology Program
Sloan Kettering Institute
Member, Departments of Medicine and Pediatrics
Memorial Sloan Kettering Cancer Center
New York, NY

Eric Sievers, MD
Senior Vice President, Clinical Development
Seattle Genetics, Inc.
Bothell, WA

This activity is primarily for researchers in hematology/oncology, and for hematologists and oncologists who diagnose and treat patients with hematologic malignancies; it is also intended for others with an interest in hematologic malignancies. This program is designed to provide the intended audience with the most current and accurate information about therapeutic advances in immunology for treating and improving outcomes for patients with hematologic malignancies.

There have been numerous attempts by cancer researchers, spanning decades, to harness the immune system to destroy cancer cells.1 In the last few years, advances in the field of immunology have led to greater understanding for how to manipulate the body’s own defenses to improve outcomes for patients with hematologic malignancies, and we are now seeing interesting results. 2-5 The most promising areas of research and emerging immunologic treatments include tumor-specific T-cell directed therapies, antibody drug conjugates, immune checkpoint targets and small molecule immunomodulatory drugs. In order to achieve better outcomes for patients, it is critical that researchers and clinicians are informed about both the application of immunology to future research, and also to disease management. In addition, it is also essential to understand how to move immunologic strategies forward in a timely fashion.


1 Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. Dec 22, 2011;480(7378):480-489.
2 Porter DL, Kalos M, Zheng Z, Levine B, June C. Chimeric Antigen Receptor Therapy for B-cell Malignancies. J Cancer. 2011;2:331-332.
3 Hanley PJ, Shaffer DR, Cruz CR, Ku S, Tzou B, Liu H, Demmler-Harrison G, Heslop HE, Rooney CM, Gottschalk S, Bollard CM. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011 Sep;13(8):976-986.
4 Buchner M, Brantner P, Stickel N, Prinz G, Burger M, Bär C, Dierks C, Pfeifer D, Ott A, Mertelsmann R, Gribben JG, Veelken H, Zirlik K. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies. Br J Haematol. 2010 Oct;151(2):167-178.
5 Zamarin D, Devlin SM, Arcila ME, Landau H, Lesokhin A, Lendvai N, Chung DJ, Chimento D, Weltz J, Babu D, Giralt S, Hassoun H. Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance. Leukemia. 2013 Dec;27(12):2422-2124.

After completing this activity, the participant should be better able to:

  • Describe advances in current understanding of immunology as they pertain to the treatment of hematologic malignancies
  • Explain the current status and therapeutic potential of immunotherapies for several hematologic malignancies
  • Demonstrate the ability to identify patients with hematologic malignancies who are appropriate candidates for an immuno-oncology treatment approach and engage them in discussions regarding clinical trials
  • Describe key factors related to moving immunotherapies forward in a timely fashion
  • Discuss the current technological advances, as well as the evolving knowledge about tumor targets, contributing to clinical advances using antibody drug conjugates to treat hematologic malignancies


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Leukemia & Lymphoma Society, RMEI, LLC and Postgraduate Institute for Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

There is no fee for this educational activity.

Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact us prior to the live event at (866) 992-9950, extension 338.

This activity is jointly provided by The Leukemia & Lymphoma Society, RMEI, LLC and Postgraduate Institute for Medicine. Funding provided by The Leukemia & Lymphoma Society.


Facebook Twitter YouTube

For information on leukemia, lymphoma or myeloma contact an LLS Information Specialist at (800) 955-4572 or Or visit